Topic: Amyloid, tau and blood-test diagnosis
ResumenLa llegada de los anticuerpos monoclonales lecanemab y donanemab marca un cambio de paradigma en el tratamiento de la enfermedad de Alzheimer, transitando del nihilismo terapéutico a la era de las terapias modificadoras de la enfermedad.Estos fármacos han demostrado una reducción significativa de la carga de amiloide cerebral y una ralentización del deterioro cognitivo en estadios tempranos.Sin embargo, su implementación en el Sistema Nacional de Salud español plantea desafíos logísticos y estructurales sin precedentes.El éxito de estas terapias depende de una «triple revolución»: un diagnóstico biológico de precisión mediante biomarcadores, una monitorización estricta de la seguridad para gestionar las anomalías de imagen relacionadas con el amiloide (ARIA) y una reingeniería del proceso asistencial para seleccionar de forma proactiva aquellos pacientes potencialmente candidatos.Factores como el genotipo ApoE y la disponibilidad de neuroimagen son críticos para la selección y seguimiento de pacientes.En conclusión, aunque estos fármacos representan un hito histórico, su viabilidad real exige una inversión decidida en unidades especializadas y una coordinación multidisciplinar que garantice la equidad y seguridad en el acceso a la innovación.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Martínez, D. A. P. (2026). Anticuerpos monoclonales antiamiloide y enfermedad de Alzheimer: ¿estamos preparados? Kranion. https://doi.org/10.24875/kranion.m26000124
Vancouver
Martínez DAP. Anticuerpos monoclonales antiamiloide y enfermedad de Alzheimer: ¿estamos preparados? Kranion. 2026. doi:10.24875/kranion.m26000124.
BibTeX
@article{martinez2026-d85edb6b,
author = {Martínez, David A. Pérez},
title = {{Anticuerpos monoclonales antiamiloide y enfermedad de Alzheimer: ¿estamos preparados?}},
journal = {Kranion},
year = {2026},
doi = {10.24875/kranion.m26000124},
url = {https://doi.org/10.24875/kranion.m26000124}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- ResumenLa llegada de los anticuerpos monoclonales lecanemab y donanemab marca un cambio de paradigma en el tratamiento de la enfermedad de Alzheimer, transitando del nihilismo terapéutico a la era de las terapias modificadoras de la enfermedad.Estos fármacos han demostrado una reducción significativ
Why it matters
The monoclonal antibodies lecanemab and donanemab reduce brain amyloid and slow cognitive decline in early stages, marking a shift toward disease-modifying therapies. However, their use in Spain's National Health System requires a triple revolution: precise biological diagnosis, strict safety monitoring for amyloid-related imaging abnormalities (ARIA), and reorganization of care to select candidates, with ApoE genotype and neuroimaging availability being critical.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 27 of the 96 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Kranion) |
| Journal's citation record | 0 / 4 | Kranion: journal h-index 2 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author David A. Pérez Martínez holds only 8 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Hospital Universitario 12 De Octubre: institution h-index 428 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 27 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 27 of the 96 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Genetics
Also in Genetics
216 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.